medigraphic.com
ISSN 1561-302X (Print)

2020, Number 3

<< Back Next >>

Rev cubana med 2020; 59 (3)

Update of the National Program and Rules of Procedure for the prevention and control of tuberculosis in Cuba

del Pino RI

Language: Spanish
References: 17
Page: 1-6
PDF size: 242.85 Kb.


ABSTRACT

The 2013 National Program and Rules of Procedure for the Prevention and Control of Tuberculosis in Cuba constitutes the daily work guide of health personnel for the management of the disease. This Program and Rules of Procedure needs to be updated to meet the new conditions and challenges posed by tuberculosis in line with local experiences and international recommendations seeking to standardize care. Modificatins are needed for terms of case classification, new diagnostic methods need to be included (imaging, immunological and genotypic) and basically on the subject of treatment with the integration of new drugs, therapeutic forms and the reorganization of drugs according to their effectiveness.


REFERENCES

  1. Ministerio de Salud Pública. Programa Nacional y Normas de procedimiento para la Prevención y Control de la Tuberculosis en Cuba, La Habana, 2013.

  2. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation5. using mathematical modelling. PLoS Med. 2016;13(10):e1002152.

  3. García García JM, Palacios Gutiérrez JJ. Tuberculosis pulmonar: etiología, patogenia, epidemiología, clínica y diagnóstico. En Álvarez-Sala J, Casan P, Rodríguez de Castro F, Rodríguez Hermosa JL, Villena Garrido V, editores. Neumología Clínica, 2.ª Edición. Barcelona: Elsevier, España, 2016. Capítulo 40. p. 322-30.

  4. Steingart KR, Schiller I, Home DJ, Pai M, Boehme C, Dendukuri N. Xpert(r) MTB/RIF assay30. for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Review. 2014;1:CD009593.

  5. Caminero JA, Cayla JA, García-García J, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnóstico y tratamiento de la tuberculosis resistente a fármacos. Arch Bronconeumol. 2017;53:501-9.

  6. Gutiérrez JJ. Utilidad de los métodos fenotípicos y genotípicos en el estudio de resistencias de Mycobacterium tuberculosis a fármacos antituberculosos de primera línea. Arch Bronconeumol. 2017;53:192-8.

  7. Caminero Luna JA. A tuberculosis guide for specialist physicians. In: Disease IUATaL,2. Paris: Imprimerie Chirat. 2004. p. 1-411.

  8. Hinshaw HC, Feldman WH. Streptomycin in treatment of clinical tuberculosis: a preliminary. Proc Staff Meet Mayo Clin. 1945;20:314-8.

  9. Farga V, Caminero JA. Tuberculosis. 3ra ed. Santiago de Chile: Editorial Mediterráneo6. Ltda; 2011. p. 484.

  10. Caminero JA, Van Deun A, Fujiwara PI, Monedero I, Chiang CY, Rieder HL, et al. Guidelines for clinical and operational management of drug-resistant tuberculosis. Paris: International Union Against Tuberculosis and Lung Disease, 2013.

  11. Scardigli A, Caminero JA. Management of drug-resistant tuberculosis. Curr Respir Care Rep. 2013;2:208-17.

  12. World Health Organization Regional Office for Europe. Algorithm for laboratory diagnosis and treatment-monitoring of pulmonary tuberculosis and drug-resistant tuberculosis using state-of-the-art rapad molecular diagnostic technologies. Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region. Copenhagen, WHO Regional Office for Europe, 2017[acceso: 26/11/2019]. Disponible en: https://erj.ersjournals.com/content/erj/51/5/1702678.full.pdf

  13. Moreno-Marín MP, Romero-Bordón SK, Sánchez-Robayo J, Santamaría-Alza Y, Mendoza. Herrera T, Bolivar-Grimaldos F. Secuelas estructurales y funcionales de tuberculosis pulmonar: una revisión del tema. Revista Americana Medicina Respiratoria. 2016;2:163-9.

  14. Tb Care I. International Standards for Tuberculosis Care, Edition 3. TB CARE I, The31. Hague, 2014[acceso: 26/11/2019]. Disponible en: Disponible en: http://www.istcweb.org

  15. Lange B, Khan P, Kalmambetova G, Al-Darraji HA, Alland D, Antonenka U, et al. Diagnostic. accuracy of the Xpert W MTB/RIF cycle threshold level to predict smear positivity: a meta- análisis. Int J Tuberc Lung Dis. 2017;21:493-502. Doi: https://doi.org/10.5588/ijtld.16.0702

  16. Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bull World Health Organ. 2017;95(8):584-93.

  17. Framework for the engagement of all health care providers in the management of drug resistant tuberculosis. Geneva, World Health Organization. 2015[acceso: 26/11/2019]. Disponible en: http://apps.who.int/iris/bitstream/10665/176152/1/9789241508919_eng.pdf.




2020     |     www.medigraphic.com